MARGARET MARTIN

DLA PIPER LLP (US) · Washington, DC · registered since 2024

Registered · LDAActive

Send proposal →Contact →Claim this profile →

At a glance

Registered since

2024

Senate LDA system

Clients

last 3 years

Filings

2 agencies contacted

Activity

filings by quarter

Works on

Health Issues 11 Medical/Disease Research/Clinical Labs 3

Background

Government experience

Senior FDA Policy Advisor

Senate Health, Education, Labor and Pensions Committee; Health Policy Assistant, Sen. Richard Burr

Disclosed on LD-2 filings

Career

DLA PIPER LLP (US)

Washington, DC

2024 - present

Specific issues

Pharmaceutical supply chain security and resiliency.

Health Issues · 2024 Q3

Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.

Medical/Disease Research/Clinical Labs · 2024 Q3

Advocating for regulatory enforcement of pharmacy compounders manufacturing approved drug products.

Health Issues · 2024 Q3

Pharmacy benefit manager reform, intellectual property issues, and other drug pricing related issues.

Health Issues · 2024 Q3

Education and advocacy related to FDA review of drug development tools.

Health Issues · 2024 Q1

Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023.

Medical/Disease Research/Clinical Labs · 2024 Q1